Current Portfolio
Using active-graph machine learning (ML) combined with single-cell analysis and deep clinical insights to advance therapeutic candidates for diseases with no or few good medicines.
Unlocking the potential of microfluidics and machine learning to discover modulators of biomolecular condensates in human disease.
Rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency.
Using AI to rapidly accelerate drug discovery and development for rare genetic and chronic diseases.
Changing the way complex medicines are made and distributed by leveraging technology innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
Closing gaps in care and improving lives for diverse patient populations through technology-based patient engagement solutions.
Developing novel technology for cell-specific delivery of CRISPR-Cas9 payloads, a major challenge for gene editing today.
Developing first-in-class drugs that target dormant disseminated tumor cells to help prevent the recurrence of cancer.
Using state of the art antibody discovery and optimization strategies, selectively inhibits extracellular enzymes that, when overactive, can cause broad inflammatory response.
Safeguarding birth control through robust technology that addresses the pain points and obstacles of effective birth control.
Pioneering evidence-based, immersive VRx—a new category of prescription digital therapeutics—including its product EaseVRx, the first virtual reality-based treatment for pain to receive FDA approval as a Class II medical device.